A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

← catalyst calendar

NCT07116031 · readout in 767 d

Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Meiji Seika Pharma Co., Ltd..

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

37estimated

Sites

Countries

Belgium, Canada, China +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-12-02

actual

When the study began enrolling

Primary completion

2028-09-25

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2031-02-28

estimated

The whole study's end, after follow-up

First posted

2025-08-11

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-05

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Chronic Graft Versus Host Disease

Interventions

Drug: Belumosudil — also filed as SAR445761, REZUROCK
Drug: Belumosudil — also filed as SAR445761, REZUROCK

Primary outcomes

what the primary-completion date above is the date OF

Phase 1: AUC

measured Cycle 1 Day 15 after the last participant dosed in the phase 1 part.

Proportion of participants who achieve an overall response (partial response [PR] or complete response [CR]) by Week 25 or Cycle 7 Day 1 whichever is first

measured Last participant completing 24 weeks (Week 25 visit or Cycle 7 Day 1 visit, whichever comes first) in the study

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed